Partners to Develop and Commercialize New Cancer Therapeutic Drugs

German and French biopharmaceutical companies have agreed to cooperate in the development and commercialization of new cancer therapeutics based on drugs that eliminate cancer cells by activating the TLR3 (Toll-like receptor 3) pathway.

Riboxx Pharmaceuticals (Radebeul, Germany) a biotech company developing Toll-like receptor (TLR) and RIG-I-like-Receptor (RLR) ligands, and Tollys SAS (Lyon, France), a biotech company developing new cancer therapeutic strategies, have signed a license agreement. The agreement grants Tollys exclusive global development and commercialization rights to the new APOXXIM drug development program.

TLR3 is a member of the Toll-like receptor (TLR) family, which plays a fundamental role in pathogen recognition and activation of innate immunity. TLRs are highly conserved from Drosophila to humans and share structural and functional similarities. They recognize pathogen-associated molecular patterns (PAMPs) that are expressed on infectious agents, and mediate the production of cytokines necessary for the development of effective immunity. RIG-I-like receptors are a type of intracellular pattern recognition receptor involved in the recognition of viruses by the innate immune system.

APOXXIM is a TLR3-ligand that eliminates cancer cells by activating the TLR3 pathway. It displays unique physical, chemical, and biological properties, with increased stability to degradation in body fluids such as human plasma. APOXXIM is manufactured according to Riboxx's unique, patented cGMP TENPORA Process.

Under the terms of the license agreement, Tollys will assume sole responsibility for global development and commercialization of APOXXIM. Riboxx will be responsible for manufacturing and supplying APOXXIM to Tollys.

Jacques Rohayem, CEO and CSO of Riboxx Pharmaceuticals said, "We are very thrilled to start this collaboration with Tollys, a company with a very strong scientific expertise in cancer therapy. This collaboration expands the portfolio of Riboxx drug development programs such as RIBOXXIM, RIBOXXOL and QUADROXXIM, mainly focusing on cancer immunotherapy."

Jacques-François Martin, president of Tollys, said, "Tollys is very pleased to start this collaboration towards the development of a new and unique therapeutic strategy in cancer. The potential of TLR3-ligands such as APOXXIM to treat cancer has been extensively studied in the past decades by scientists at Tollys, with a particular focus on TLR3-positive cancers."

Related Links:
Riboxx Pharmaceuticals